RAPT Therapeutics (NASDAQ:RAPT) reported quarterly losses of $(0.63) per share. This is unchanged from the same period last year.
CIBC Downgrades Conifex Timber to Underperformer, Announces C$1.5 Price Target
CIBC analyst Hamir Patel downgrades Conifex Timber (TSX:CFF) from Neutral to Underperformer and announces C$1.5 price target.